Reviva Pharmaceuticals (RVPH) Competitors

Reviva Pharmaceuticals logo
$0.34 +0.05 (+17.96%)
As of 11/20/2026 03:57 PM Eastern

RVPH vs. COCP, LPCN, QNRX, TAOX, and CTXR

Should you buy Reviva Pharmaceuticals stock or one of its competitors? Reviva Pharmaceuticals's main competitors and comparable companies include Cocrystal Pharma (COCP), Lipocine (LPCN), Quoin Pharmaceuticals (QNRX), Synaptogenix (TAOX), and Citius Pharmaceuticals (CTXR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Reviva Pharmaceuticals compare to Cocrystal Pharma?

Cocrystal Pharma (NASDAQ:COCP) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Cocrystal Pharma has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market.

Cocrystal Pharma's return on equity of -320.01% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Cocrystal PharmaN/A -320.01% -158.73%
Reviva Pharmaceuticals N/A -391.58%-119.08%

6.7% of Cocrystal Pharma shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 39.4% of Cocrystal Pharma shares are owned by company insiders. Comparatively, 5.1% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cocrystal PharmaN/AN/A-$8.83M-$0.77N/A
Reviva PharmaceuticalsN/AN/A-$19.86M-$0.82N/A

In the previous week, Cocrystal Pharma had 13 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 16 mentions for Cocrystal Pharma and 3 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.25 beat Cocrystal Pharma's score of 0.33 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cocrystal Pharma
1 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Reviva Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Reviva Pharmaceuticals has a consensus price target of $53.33, suggesting a potential upside of 15,820.40%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Cocrystal Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cocrystal Pharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Summary

Reviva Pharmaceuticals beats Cocrystal Pharma on 7 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

Lipocine has higher revenue and earnings than Reviva Pharmaceuticals. Lipocine is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipocine$1.98M8.27-$9.63M-$1.28N/A
Reviva PharmaceuticalsN/AN/A-$19.86M-$0.82N/A

Lipocine has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Lipocine currently has a consensus price target of $4.00, indicating a potential upside of 170.27%. Reviva Pharmaceuticals has a consensus price target of $53.33, indicating a potential upside of 15,820.40%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Lipocine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

In the previous week, Lipocine and Lipocine both had 3 articles in the media. Lipocine's average media sentiment score of 1.30 beat Reviva Pharmaceuticals' score of 1.25 indicating that Lipocine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lipocine
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Reviva Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 4.7% of Lipocine shares are owned by insiders. Comparatively, 5.1% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -249.23%. Lipocine's return on equity of -46.52% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Lipocine-249.23% -46.52% -41.75%
Reviva Pharmaceuticals N/A -391.58%-119.08%

Summary

Reviva Pharmaceuticals beats Lipocine on 9 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Quoin Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 4 mentions for Quoin Pharmaceuticals and 3 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.25 beat Quoin Pharmaceuticals' score of 0.22 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Reviva Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$0.82N/A
Quoin PharmaceuticalsN/AN/A-$15.81M-$19.44N/A

Reviva Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.71, suggesting that its share price is 71% more volatile than the broader market.

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 5.1% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 7.5% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Quoin Pharmaceuticals' return on equity of -227.75% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
Quoin Pharmaceuticals N/A -227.75%-149.97%

Reviva Pharmaceuticals presently has a consensus price target of $53.33, indicating a potential upside of 15,820.40%. Quoin Pharmaceuticals has a consensus price target of $17.00, indicating a potential upside of 418.29%. Given Reviva Pharmaceuticals' higher probable upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Quoin Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Quoin Pharmaceuticals beats Reviva Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Synaptogenix?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Synaptogenix (NASDAQ:TAOX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, risk, profitability, media sentiment and institutional ownership.

Reviva Pharmaceuticals has a net margin of 0.00% compared to Synaptogenix's net margin of -768.22%. Synaptogenix's return on equity of -68.89% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
Synaptogenix -768.22%-68.89%-49.33%

Reviva Pharmaceuticals has higher earnings, but lower revenue than Synaptogenix. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$0.82N/A
Synaptogenix$300K41.54-$28.74M-$3.85N/A

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 5.1% of Reviva Pharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Synaptogenix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Reviva Pharmaceuticals had 1 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 2 mentions for Synaptogenix. Reviva Pharmaceuticals' average media sentiment score of 1.25 beat Synaptogenix's score of -0.65 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Reviva Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Synaptogenix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative

Reviva Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.81, meaning that its share price is 81% more volatile than the broader market.

Reviva Pharmaceuticals currently has a consensus target price of $53.33, indicating a potential upside of 15,820.40%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Synaptogenix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Synaptogenix
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Reviva Pharmaceuticals beats Synaptogenix on 10 of the 15 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Citius Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Reviva Pharmaceuticals has higher earnings, but lower revenue than Citius Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$0.82N/A
Citius Pharmaceuticals$7.11M1.96-$37.43M-$1.67N/A

In the previous week, Reviva Pharmaceuticals had 2 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 1 mentions for Citius Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.25 beat Citius Pharmaceuticals' score of -0.71 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Reviva Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Citius Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are held by institutional investors. 5.1% of Reviva Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Citius Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals currently has a consensus target price of $53.33, indicating a potential upside of 15,820.40%. Citius Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 1,079.94%. Given Reviva Pharmaceuticals' higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Citius Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Citius Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Reviva Pharmaceuticals has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Citius Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

Citius Pharmaceuticals' return on equity of -59.57% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
Citius Pharmaceuticals N/A -59.57%-34.47%

Summary

Reviva Pharmaceuticals and Citius Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVPH vs. The Competition

MetricReviva PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.93M$13.12B$7.44B$10.86B
Dividend YieldN/A2.62%2.51%4.69%
P/E Ratio-0.4127.8232.5628.72
Price / SalesN/A7.078.005.34
Price / CashN/A15.2220.2520.77
Price / Book0.235.164.343.51
Net Income-$19.86M$2.86B$3.51B$394.12M
7 Day Performance-5.18%-7.27%-8.07%-8.97%
1 Month Performance-22.27%-9.60%-10.29%-11.61%
1 Year Performance-96.73%-9.28%-4.70%-11.21%

Reviva Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVPH
Reviva Pharmaceuticals
2.5459 of 5 stars
$0.34
+18.0%
$53.33
+15,820.4%
-96.7%$3.93MN/AN/A14
COCP
Cocrystal Pharma
0.9471 of 5 stars
$0.98
-0.3%
N/A+5.4%$18.78MN/AN/A10
LPCN
Lipocine
4.2246 of 5 stars
$1.61
-3.3%
$4.00
+149.1%
-53.2%$17.99M$1.98MN/A14
QNRX
Quoin Pharmaceuticals
4.0112 of 5 stars
$3.48
-2.2%
$17.33
+398.1%
-82.1%$16.70MN/AN/A4
TAOX
Synaptogenix
0.4568 of 5 stars
$1.87
+0.3%
N/A-75.8%$15.00M$300KN/A4

Related Companies and Tools


This page (NASDAQ:RVPH) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners